WuXi ATU opens new manufacturing facility in Shanghai
CDTMO’s fourth site further expands its support of cell therapy delivery and access
WuXi Advanced Therapies Inc. (WuXi ATU), a contract, testing, development and manufacturing organization (CTDMO) and wholly owned subsidiary of WuXi AppTec, is opening its new process development and commercial manufacturing facility in Lin-gang, Shanghai. This marks the company’s fourth manufacturing site worldwide, joining other sites in the US, UK and China.
The Lin-gang site provides integrated development, manufacturing, and testing services for viral vectors and cell therapies. It has more than 200 independent suites and six complete production lines, along with an independent liquid distribution center and independent good manufacturing practice (GMP) standard sterile filling isolator. These resources—according to WuXi ATU officials—are expected to further strengthen the CTDMO’s global operations by providing customers with more flexibility and speed when it comes to viral vector and cell therapy delivery.
"… By expanding our global footprint,” says Dr. David Chang, CEO of WuXi ATU, “we will provide enhanced cell and gene therapy manufacturing services for our customers worldwide and better enable them to deliver more effective and accessible advanced therapies to patients."
